Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes

ObjectsImigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function in Chinese patients with type-2 diabetes mellitus (T2DM).MethodsA total of 37 Chinese T2DM patients were ran...

Full description

Bibliographic Details
Main Authors: Xu Liu, Yang Liu, Hongzhong Liu, Haiyan Li, Jianhong Yang, Pei Hu, Xinhua Xiao, Dongyang Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Endocrinology
Subjects:
DPP-4 inhibitor
imigliptin
alogliptin
diabetes
oral minimal model
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.694390/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.694390/full

Similar Items